Holger W Auner
Auner, Holger
VIAF ID: 985149844939602960005 (Personal)
Permalink: http://viaf.org/viaf/985149844939602960005
Preferred Forms
-
100 1 _
‡a
Auner, Holger
-
100 0 _
‡a
Holger W Auner
4xx's: Alternate Name Forms (5)
5xx's: Related Names (2)
Works
| Title | Sources |
|---|---|
| Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. |
|
| Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits |
|
| Bi-directional cell-pericellular matrix interactions direct stem cell fate |
|
| Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure |
|
| Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma |
|
| The coordinated action of VCP/p97 and GCN2 regulates cancer cell metabolism and proteostasis during nutrient limitation |
|
| Correspondence re: O. J. Arola et al., acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. Cancer Res., 60: 1789-1792, 2000 |
|
| Cutaneous presentation of an aggressive plasmablastic neoplasm indiscriminate between lymphoma and myeloma |
|
| Differential Regulation of Human Bone Marrow Mesenchymal Stromal Cell Chondrogenesis by Hypoxia Inducible Factor-1α Hydroxylase Inhibitors |
|
| An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties |
|
| ER stress and cancer: The FOXO forkhead transcription factor link. |
|
| From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. |
|
| The HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death |
|
| High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. |
|
| Inadequate fine-tuning of protein synthesis and failure of amino acid homeostasis following inhibition of the ATPase VCP/p97 |
|
| LACE-conditioned autologous stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma: treatment outcome and risk factor analysis from a single centre |
|
| The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. |
|
| Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). |
|
| Melphalan 140mg/m2 or 200mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party. |
|
| Molecular typing of coagulase-negative staphylococcal blood and skin culture isolates to differentiate between bacteremia and contamination |
|
| Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide |
|
| More convenient proteasome inhibition for improved outcomes |
|
| Mutational analysis of the DNA mismatch repair gene hMLH1 in myeloid leukaemias |
|
| Neighboring cells override 3D hydrogel matrix cues to drive human MSC quiescence |
|
| A novel role for the Aurora B kinase in epigenetic marking of silent chromatin in differentiated postmitotic cells. |
|
| Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. |
|
| Oral and intestinal Candida colonization in patients undergoing hematopoietic stem-cell transplantation. |
|
| Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN) |
|
| Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3 |
|
| Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension |
|
| Proteasome inhibition in multiple myeloma: lessons for other cancers |
|
| Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis |
|
| Recent advances and future directions in targeting the secretory apparatus in multiple myeloma. |
|
| Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation |
|
| Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red cell aplasia refractory to conventional treatment |
|
| Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor |
|
| Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting). |
|
| Successful nonsurgical treatment of primary mucosa-associated lymphoid tissue lymphoma of colon presenting with multiple polypoid lesions |
|
| Time from first symptom onset to the final diagnosis of multiple myeloma (MM) - possible risks and future solutions: retrospective and prospective 'Deutsche Studiengruppe MM' (DSMM) and 'European Myeloma Network' (EMN) analysis |
|
| Treatment options for relapse after autograft in multiple myeloma - report from an EBMT educational meeting. |
|
| Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. |
|
| Troponins in prediction of cardiotoxic effects |
|
| Two case studies of chronic idiopathic neutropenia preceding acute myeloid leukaemia. |
|
| Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia |
|
| Which lumen is the source of catheter-related bloodstream infection in patients with multi-lumen central venous catheters? |
|
